Literature DB >> 16552535

[Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment].

T Ness1, C Auw-Hädrich, D Schmidt.   

Abstract

Giant cell arteritis (arteritis temporalis) is the most common form of systemic vasculitis in the elderly. A series of symptoms such as new-onset headache, jaw claudication, proximal myalgia, weight loss, and fever may lead to the diagnosis. However, there is also a silent or occult presentation with minor or no systemic symptoms, especially no headache. A number of laboratory values (erythrocyte sedimentation rate, CRP, fibrinogen, thrombocytes, and cardiolipin antibodies) indicate giant cell arteritis, but none of this proves the diagnosis. Temporal artery biopsy is the gold standard for diagnosis of giant cell arteritis. Due to skip lesions, a negative result does not exclude the diagnosis. The most important complication of giant cell arteritis is visual loss in one or both eyes due to AION or retinal artery occlusion. Usually, visual loss is irreversible even with therapy. Corticosteroids are the drug of choice to treat giant cell arteritis. Therapy is required for a long time, monitored by parameters of inflammation (ESR, CRP).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552535     DOI: 10.1007/s00347-006-1324-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  67 in total

1.  Steroid therapy for visual loss in patients with giant-cell arteritis.

Authors:  S S Hayreh
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

2.  Sudden death after treatment with pulsed methylprednisolone.

Authors:  P V Gardiner; I D Griffiths
Journal:  BMJ       Date:  1990-01-13

3.  Occult giant cell arteritis: ocular manifestations.

Authors:  S S Hayreh; P A Podhajsky; B Zimmerman
Journal:  Am J Ophthalmol       Date:  1998-04       Impact factor: 5.258

4.  Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study.

Authors:  G Nesher; A Rubinow; M Sonnenblick
Journal:  Clin Exp Rheumatol       Date:  1997 May-Jun       Impact factor: 4.473

5.  The importance of skip lesions in temporal arteritis.

Authors:  D N Poller; Q van Wyk; M J Jeffrey
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

6.  Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients.

Authors:  G Nesher; M Sonnenblick; Y Friedlander
Journal:  J Rheumatol       Date:  1994-07       Impact factor: 4.666

7.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

8.  Long-term corticosteroid treatment in giant cell arteritis.

Authors:  R Andersson; B E Malmvall; B A Bengtsson
Journal:  Acta Med Scand       Date:  1986

9.  Prevention of blindness in giant cell arteritis by corticosteroid treatment.

Authors:  A B Myles; T Perera; M G Ridley
Journal:  Br J Rheumatol       Date:  1992-02

10.  Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy.

Authors:  C Salvarani; P L Macchioni; P L Tartoni; F Rossi; R Baricchi; C Castri; F Chiaravalloti; I Portioli
Journal:  Clin Exp Rheumatol       Date:  1987 Jul-Sep       Impact factor: 4.473

View more
  10 in total

1.  Headache, palsy, and an elevated ESR: not necessarily giant cell arteritis.

Authors:  Gennady Landa; Ayala Pollack; Hana Leiba
Journal:  Can Fam Physician       Date:  2007-06       Impact factor: 3.275

2.  Retinal vascular occlusions: an interdisciplinary challenge.

Authors:  Alireza Mirshahi; Nicolas Feltgen; Lutz L Hansen; Lars-Olof Hattenbach
Journal:  Dtsch Arztebl Int       Date:  2008-06-27       Impact factor: 5.594

3.  [Acute visual loss with bilateral corneal edema].

Authors:  C Raum; C Y Mardin
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

4.  [Clinical aspects of temporal arteritis: course variations up to fatal complications].

Authors:  A Brüggemann; K Holl-Ulrich; M Müller
Journal:  Ophthalmologe       Date:  2010-10       Impact factor: 1.059

Review 5.  The diagnosis and treatment of giant cell arteritis.

Authors:  Thomas Ness; Thorsten A Bley; Wolfgang A Schmidt; Peter Lamprecht
Journal:  Dtsch Arztebl Int       Date:  2013-05-24       Impact factor: 5.594

6.  [Ophthalmological findings as a hint for systemic disease].

Authors:  W A Herrmann; H Helbig; M A Gamulescu
Journal:  Internist (Berl)       Date:  2010-04       Impact factor: 0.743

Review 7.  [Ocular involvement in connective tissue diseases and vasculitides].

Authors:  C Deuter; I Kötter
Journal:  Z Rheumatol       Date:  2010-07       Impact factor: 1.372

Review 8.  [Ocular findings and differential diagnoses in giant cell arteritis (Arteriitis cranialis)].

Authors:  D Schmidt; T Ness
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

9.  Atypical presentation of giant cell arteritis in a patient with vertebrobasilar stroke: A case report.

Authors:  Ahmed Mohamed Elhfnawy; Michael Bieber; Mira Schliesser; Peter Kraft
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 10.  [Rheumatological emergency on the edge of intensive care medicine].

Authors:  Peter Härle
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.